Puma Biotechnology Inc PBYI Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Mar 15, 2024 (filed on Mar 19, 2024)

Insider Name:

Auerbach Alan H

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

9,047

Price:

--
Mar 15, 2024 (filed on Mar 19, 2024)

Insider Name:

Auerbach Alan H

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

6,577

Price:

--
Feb 12, 2024 (filed on Feb 14, 2024)

Insider Name:

Wong Alvin F

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

59,946

Price:

--
Feb 12, 2024 (filed on Feb 14, 2024)

Insider Name:

Wong Alvin F

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

43,307

Price:

--
Feb 12, 2024 (filed on Feb 14, 2024)

Insider Name:

Nougues Maximo F

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

59,946

Price:

--
Feb 12, 2024 (filed on Feb 14, 2024)

Insider Name:

Nougues Maximo F

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

43,307

Price:

--
Feb 12, 2024 (filed on Feb 14, 2024)

Insider Name:

Ludwig Jeffrey Jerome

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

37,466

Price:

--
Feb 12, 2024 (filed on Feb 14, 2024)

Insider Name:

Ludwig Jeffrey Jerome

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

27,067

Price:

--
Feb 12, 2024 (filed on Feb 14, 2024)

Insider Name:

Auerbach Alan H

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

222,573

Price:

--
Feb 12, 2024 (filed on Feb 14, 2024)

Insider Name:

Auerbach Alan H

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

160,796

Price:

--

Filings by filing date

Mar 15, 2024 (filed on Mar 19, 2024)

Insider Name:

Auerbach Alan H

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

9,047

Price:

--
Mar 15, 2024 (filed on Mar 19, 2024)

Insider Name:

Auerbach Alan H

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

6,577

Price:

--
Feb 12, 2024 (filed on Feb 14, 2024)

Insider Name:

Wong Alvin F

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

59,946

Price:

--
Feb 12, 2024 (filed on Feb 14, 2024)

Insider Name:

Wong Alvin F

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

43,307

Price:

--
Feb 12, 2024 (filed on Feb 14, 2024)

Insider Name:

Nougues Maximo F

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

59,946

Price:

--
Feb 12, 2024 (filed on Feb 14, 2024)

Insider Name:

Nougues Maximo F

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

43,307

Price:

--
Feb 12, 2024 (filed on Feb 14, 2024)

Insider Name:

Ludwig Jeffrey Jerome

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

37,466

Price:

--
Feb 12, 2024 (filed on Feb 14, 2024)

Insider Name:

Ludwig Jeffrey Jerome

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

27,067

Price:

--
Feb 12, 2024 (filed on Feb 14, 2024)

Insider Name:

Auerbach Alan H

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

222,573

Price:

--
Feb 12, 2024 (filed on Feb 14, 2024)

Insider Name:

Auerbach Alan H

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

160,796

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	10880 Wilshire Blvd., Suite 2150 LOS ANGELES CA 90024
Tel:	1-424-2486500
Website:	https://www.pumabiotechnology.com
IR:	See website

Key People

Alan H. Auerbach Chairman of the Board, President, Chief Executive Officer, Secretary	Maximo F. Nougues Chief Financial Officer	Douglas Hunt Senior Vice President - Regulatory Affairs, Medical Writing and Project Management
Alvin Wong Chief Scientific Officer	Jeff J. Ludwig Chief Commercial Officer

Business Overview

Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to enhance cancer care. The Company's lead product is NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Neratinib is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2 and HER4 It also engaged in the development and commercialization of, alisertib. Alisertib is a selective, small molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.

Financial Overview

For the fiscal year ended 31 December 2023, Puma Biotechnology Inc revenues increased 3% to $235.6M. Net income increased from $2K to $21.6M. Revenues reflect Royalty revenue increase of 16% to $32.5M, Product Revenue, net increase of 2% to $203.1M. Net income benefited from Legal verdict expense decrease from $12.5M (expense) to $0K, Professional fees and expenses decrease of 11% to $34M (expense).

Employees:	185 as of Dec 31, 2023

Reporting Currency:	U.S. Dollars
Enterprise value:	$238.97M as of Dec 31, 2023
Annual revenue (TTM):	$235.64M as of Dec 31, 2023
EBITDA (TTM):	$44.78M as of Dec 31, 2023
Net annual income (TTM):	$21.59M as of Dec 31, 2023
Free cash flow (TTM):	$14.37M as of Dec 31, 2023
Net Debt Last Fiscal Year:	$3.72M as of Dec 31, 2023
Shares outstanding:	48,207,162 as of Feb 26, 2024
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization